Denali Therapeutics, Inc. (DNLI)
17.95
+0.87
(+5.09%)
USD |
NASDAQ |
Jan 12, 16:00
17.98
+0.03
(+0.17%)
After-Hours: 20:00
Denali Therapeutics Research and Development Expense (Quarterly): 101.95M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Enovis Corp. | 29.74M |
| Masimo Corp. | 30.50M |
| Novavax, Inc. | 98.17M |
| Protalix Biotherapeutics, Inc. | 4.467M |
| Twist Bioscience Corp. | 17.01M |